Drug design

#AI #AI / data analytics / healthtech / informatics #Cancer research #Drug design #Drug development #Drug discovery

First AI-designed immuno-oncology drug enters clinical trials

Exscientia, an artificial intelligence (AI)-driven pharmatech company, has announced the first AI-designed molecule for immuno-oncology to enter human clinical trials, a joint venture co-invented and developed by Exscientia and Evotec. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, includes the application of Exscientia’s… Read More

#Cancer Research #News

#Drug design #Pharma #Pharmaceuticals #Regulatory

Biotech consultancy has recruitment drive following surge in demand

Turnover at pharmaceutical and biotech product development consultancy Boyds has surged by 25% as demand for its specialist services continues to grow. The company has added seven regulatory and medical affairs experts to its team, and is now launching an even larger recruitment drive creating up to ten new roles… Read More

#News

#Drug design #Drug development #Drug discovery #Neuroscience #Parkinson's

IRICoR and Valence collaborate in AI drug design for Parkinson’s

IRICoR, a pan-Canadian drug discovery and research commercialisation centre, Université de Montréal (UdeM), the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, and Valence Discovery, an emerging leader in AI-enabled drug design, have announced a collaboration focused on the discovery of novel drug candidates for… Read More

#News